{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:00:11Z","timestamp":1792566011938,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.schres.2020.03.006","type":"journal-article","created":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T12:33:52Z","timestamp":1583930032000},"page":"55-62","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Indicated association between polygenic risk score and treatment-resistance in a naturalistic sample of patients with schizophrenia spectrum disorders"],"prefix":"10.1016","volume":"218","author":[{"given":"Maren Caroline Frogner","family":"Werner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-8061","authenticated-orcid":false,"given":"Katrine Verena","family":"Wirgenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit","family":"Haram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bettella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Synve Hoffart","family":"Lunding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linn","family":"R\u00f8devand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hjell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Agartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdjan","family":"Djurovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Melle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole A.","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Eiel","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.schres.2020.03.006_bb0005","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.4088\/JCP.09m05785yel","article-title":"An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis","volume":"72","author":"Agid","year":"2011","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.schres.2020.03.006_bb0010","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.neubiorev.2017.09.027","article-title":"Dopamine, the antipsychotic molecule: a perspective on mechanisms underlying antipsychotic response variability","volume":"85","author":"Amato","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.schres.2020.03.006_bb0015","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"issue":"7","key":"10.1016\/j.schres.2020.03.006_bb0020","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv016","article-title":"Extensive gray matter volume reduction in treatment-resistant schizophrenia","volume":"18","author":"Anderson","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2020.03.006_bb0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ajhg.2013.01.001","article-title":"Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors","volume":"92","author":"Andreassen","year":"2013","journal-title":"Am. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.schres.2020.03.006_bb0030","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/mp.2013.195","article-title":"Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci","volume":"20","author":"Andreassen","year":"2015","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2020.03.006_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2019.4188","article-title":"Shared genetic loci between body mass index and major psychiatric disorders: a genome-wide association study","author":"Bahrami","year":"2020","journal-title":"JAMA psychiatry"},{"key":"10.1016\/j.schres.2020.03.006_bb0040","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.psychres.2019.02.028","article-title":"Mapping cortical surface features in treatment resistant schizophrenia with in vivo structural MRI","volume":"274","author":"Barry","year":"2019","journal-title":"Psychiatry Res."},{"issue":"2","key":"10.1016\/j.schres.2020.03.006_bb0045","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.psychres.2013.06.042","article-title":"Differential cognitive performances between schizophrenic responders and non-responders to antipsychotics: correlation with course of the illness, psychopathology, attitude to the treatment and antipsychotics doses","volume":"210","author":"de Bartolomeis","year":"2013","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.schres.2020.03.006_bb0050","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.gene.2014.03.050","article-title":"Treatment-resistant schizophrenia and DAT and SERT polymorphisms","volume":"543","author":"Bilic","year":"2014","journal-title":"Gene"},{"issue":"6","key":"10.1016\/j.schres.2020.03.006_bb0055","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1093\/schbul\/sby058","article-title":"Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016","volume":"44","author":"Charlson","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2020.03.006_bb0060","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/schbul\/sby010","article-title":"Shared genetic risk of schizophrenia and gray matter reduction in 6p22.1","volume":"45","author":"Chen","year":"2019","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2020.03.006_bb0065","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/wps.20128","article-title":"Risks of all-cause and suicide mortality in mental disorders: a meta-review","volume":"13","author":"Chesney","year":"2014","journal-title":"World Psychiatry: official journal of the World Psychiatric Association (WPA)"},{"key":"10.1016\/j.schres.2020.03.006_bb0070","first-page":"357","article-title":"Global economic burden of schizophrenia: a systematic review","volume":"12","author":"Chong","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"10","key":"10.1016\/j.schres.2020.03.006_bb0075","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/ng.3656","article-title":"Next-generation genotype imputation service and methods","volume":"48","author":"Das","year":"2016","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.schres.2020.03.006_bb0080","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/oxfordjournals.schbul.a007030","article-title":"A systematic review and meta-analysis of northern hemisphere season of birth studies in schizophrenia","volume":"29","author":"Davies","year":"2003","journal-title":"Schizophr. Bull."},{"issue":"11","key":"10.1016\/j.schres.2020.03.006_bb0085","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1176\/appi.ajp.2012.12010144","article-title":"Dopamine synthesis capacity in patients with treatment-resistant schizophrenia","volume":"169","author":"Demjaha","year":"2012","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2020.03.006_bb0090","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.biopsych.2013.06.011","article-title":"Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function","volume":"75","author":"Demjaha","year":"2014","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2020.03.006_bb0095","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/YPG.0000000000000237","article-title":"Brain-derived neurotrophic factor and schizophrenia","volume":"29","author":"Di Carlo","year":"2019","journal-title":"Psychiatr. Genet."},{"issue":"3","key":"10.1016\/j.schres.2020.03.006_bb0100","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.psc.2007.04.001","article-title":"Treatment-resistant schizophrenia","volume":"30","author":"Elkis","year":"2007","journal-title":"The Psychiatric clinics of North America"},{"issue":"6","key":"10.1016\/j.schres.2020.03.006_bb0105","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/archpsyc.1976.01770060086012","article-title":"The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance","volume":"33","author":"Endicott","year":"1976","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2020.03.006_bb0110","series-title":"Structured Clinical Interview for DSM-IV Axis I Disorders: Patient Edition (SCID-P), Version 2","author":"First","year":"1995"},{"issue":"2","key":"10.1016\/j.schres.2020.03.006_bb0115","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/mp.2014.56","article-title":"Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients","volume":"20","author":"Frank","year":"2015","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2020.03.006_bb0120","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1176\/appi.ps.201400558","article-title":"Early predictors of ten-year course in first-episode psychosis","volume":"67","author":"Friis","year":"2016","journal-title":"Psychiatric services (Washington, D.C.)"},{"issue":"1","key":"10.1016\/j.schres.2020.03.006_bb0125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12888-016-1177-y","article-title":"Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review","volume":"17","author":"Gillespie","year":"2017","journal-title":"BMC psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2020.03.006_bb0130","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/2045125318781475","article-title":"The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses","volume":"8","author":"Haddad","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"issue":"19","key":"10.1016\/j.schres.2020.03.006_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20194753","article-title":"Clinical and genetic factors associated with resistance to treatment in patients with schizophrenia: a case-control study","volume":"20","author":"Hajj","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1\u221202","key":"10.1016\/j.schres.2020.03.006_bb0140","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"10.1016\/j.schres.2020.03.006_bb0145","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2020.03.006_bb0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.pscychresns.2013.10.002","article-title":"Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication","volume":"221","author":"Hutcheson","year":"2014","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2020.03.006_bb0155","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pnpbp.2015.08.010","article-title":"Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones","volume":"65","author":"Iasevoli","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2020.03.006_bb0160","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0010-440X(66)80028-7","article-title":"Therapeutic studies in \u201ctherapy resistant\u201d schizophrenic patients","volume":"7","author":"Itil","year":"1966","journal-title":"Compr. Psychiatry"},{"key":"10.1016\/j.schres.2020.03.006_bb0165","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pnpbp.2017.11.004","article-title":"Side effect burden of antipsychotic drugs in real life - impact of gender and polypharmacy","volume":"82","author":"Iversen","year":"2018","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2020.03.006_bb0170","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","article-title":"A systematic review and meta-analysis of recovery in schizophrenia","volume":"39","author":"Jaaskelainen","year":"2013","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2020.03.006_bb0175","first-page":"141","article-title":"T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability","volume":"24","author":"Joober","year":"1999","journal-title":"Journal of psychiatry & neuroscience: JPN"},{"issue":"3","key":"10.1016\/j.schres.2020.03.006_bb0180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0920-9964(01)00279-1","article-title":"Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers","volume":"53","author":"Joober","year":"2002","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2020.03.006_bb0185","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.schres.2005.01.008","article-title":"Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients","volume":"77","author":"Joober","year":"2005","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2020.03.006_bb0190","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"The Journal of clinical psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2020.03.006_bb0195","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"3","key":"10.1016\/j.schres.2020.03.006_bb0200","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.comppsych.2009.07.003","article-title":"Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia","volume":"51","author":"Kelly","year":"2010","journal-title":"Compr. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2020.03.006_bb0205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","article-title":"The social and economic burden of treatment-resistant schizophrenia: a systematic literature review","volume":"29","author":"Kennedy","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2020.03.006_bb0210","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/oxfordjournals.schbul.a007078","article-title":"The global costs of schizophrenia","volume":"30","author":"Knapp","year":"2004","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2020.03.006_bb0215","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.146.3.229","article-title":"Schizophrenia with good and poor outcome. I: early clinical features, response to neuroleptics and signs of organic dysfunction","volume":"146","author":"Kolakowska","year":"1985","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"issue":"5","key":"10.1016\/j.schres.2020.03.006_bb0220","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/pcn.12242","article-title":"Psychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesis","volume":"69","author":"Kusumi","year":"2015","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2020.03.006_bb0225","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/bmb\/ldv017","article-title":"Antipsychotic medication in schizophrenia: a review","volume":"114","author":"Lally","year":"2015","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.schres.2020.03.006_bb0230","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/PGPM.S115741","article-title":"Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics","volume":"9","author":"Lally","year":"2016","journal-title":"Pharmacogenomics and personalized medicine"},{"key":"10.1016\/j.schres.2020.03.006_bb0235","first-page":"1","article-title":"Clinical indicators of treatment-resistant psychosis","author":"Legge","year":"2019","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"issue":"9831","key":"10.1016\/j.schres.2020.03.006_bb0240","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","article-title":"Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis","volume":"379","author":"Leucht","year":"2012","journal-title":"Lancet (London, England)"},{"issue":"9896","key":"10.1016\/j.schres.2020.03.006_bb0245","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet (London, England)"},{"issue":"Suppl. 1","key":"10.1016\/j.schres.2020.03.006_bb0250","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr. Bull."},{"issue":"8","key":"10.1016\/j.schres.2020.03.006_bb0255","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/gepi.20533","article-title":"MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes","volume":"34","author":"Li","year":"2010","journal-title":"Genet. Epidemiol."},{"issue":"3","key":"10.1016\/j.schres.2020.03.006_bb0260","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1017\/S0033291715001701","article-title":"Increased rare duplication burden genomewide in patients with treatment-resistant schizophrenia","volume":"46","author":"Martin","year":"2016","journal-title":"Psychol. Med."},{"issue":"1","key":"10.1016\/j.schres.2020.03.006_bb0265","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/acps.12825","article-title":"Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia","volume":"137","author":"McCutcheon","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"issue":"4","key":"10.1016\/j.schres.2020.03.006_bb0270","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1176\/ajp.154.4.475","article-title":"Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance","volume":"154","author":"Meltzer","year":"1997","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2020.03.006_bb0275","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neubiorev.2019.07.001","article-title":"Functional neuroimaging in treatment resistant schizophrenia: a systematic review","volume":"104","author":"Molent","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"6","key":"10.1016\/j.schres.2020.03.006_bb0280","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/15622975.2015.1062552","article-title":"High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance","volume":"16","author":"Noto","year":"2015","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.schres.2020.03.006_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2018.08.016","article-title":"Treatment resistant schizophrenia: clinical, biological, and therapeutic perspectives","volume":"131","author":"Nucifora","year":"2019","journal-title":"Neurobiol. Dis."},{"issue":"10039","key":"10.1016\/j.schres.2020.03.006_bb0290","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.schres.2020.03.006_bb0295","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41588-018-0059-2","article-title":"Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection","volume":"50","author":"Pardinas","year":"2018","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.schres.2020.03.006_bb0300","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2020.03.006_bb0305","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell","year":"2007","journal-title":"Am. J. Hum. Genet."},{"issue":"7256","key":"10.1016\/j.schres.2020.03.006_bb0310","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nature08185","article-title":"Common polygenic variation contributes to risk of schizophrenia and bipolar disorder","volume":"460","author":"Purcell","year":"2009","journal-title":"Nature"},{"issue":"7510","key":"10.1016\/j.schres.2020.03.006_bb0315","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nature13595","article-title":"Biological insights from 108 schizophrenia-associated genetic loci","volume":"511","author":"Schizophrenia Working Group of the Psychiatric Genomics Consortium., S.W.G.o.t.P.G","year":"2014","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.schres.2020.03.006_bb0320","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1176\/ajp.144.10.1271","article-title":"Familial schizophrenia and treatment response","volume":"144","author":"Silverman","year":"1987","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2020.03.006_bb0325","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"issue":"4","key":"10.1016\/j.schres.2020.03.006_bb0330","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/schbul\/sbx148","article-title":"Genetic overlap between schizophrenia and volumes of hippocampus, putamen, and intracranial volume indicates shared molecular genetic mechanisms","volume":"44","author":"Smeland","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.schres.2020.03.006_bb0335","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/15622975.2016.1245441","article-title":"Serum levels of second-generation antipsychotics are associated with cognitive function in psychotic disorders","volume":"18","author":"Steen","year":"2017","journal-title":"World J Biol Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2020.03.006_bb0340","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.biopsych.2012.08.017","article-title":"Genetic schizophrenia risk variants jointly modulate total brain and white matter volume","volume":"73","author":"Terwisscha van Scheltinga","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2020.03.006_bb0345","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/acps.12307","article-title":"Polygenic risk score and the psychosis continuum model","volume":"130","author":"Tesli","year":"2014","journal-title":"Acta Psychiatr. Scand."},{"issue":"9","key":"10.1016\/j.schres.2020.03.006_bb0350","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","article-title":"The personal and clinical utility of polygenic risk scores","volume":"19","author":"Torkamani","year":"2018","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.schres.2020.03.006_bb0355","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0165-1781(98)00038-9","article-title":"Training and quality assurance with the Structured Clinical Interview for DSM-IV (SCID-I\/P)","volume":"79","author":"Ventura","year":"1998","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.schres.2020.03.006_bb0360","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-244X-14-102","article-title":"Clozapine: a review of clinical practice guidelines and prescribing trends","volume":"14","author":"Warnez","year":"2014","journal-title":"BMC psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2020.03.006_bb0365","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S2215-0366(15)00575-1","article-title":"Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study","volume":"3","author":"Wimberley","year":"2016","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2020.03.006_bb0370","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/schbul\/sbx007","article-title":"Polygenic risk score for schizophrenia and treatment-resistant schizophrenia","volume":"43","author":"Wimberley","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"7","key":"10.1016\/j.schres.2020.03.006_bb0375","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1176\/ajp.146.7.905","article-title":"Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia","volume":"146","author":"Wolkin","year":"1989","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2020.03.006_bb0380","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/jcpp.12295","article-title":"Research review: polygenic methods and their application to psychiatric traits","volume":"55","author":"Wray","year":"2014","journal-title":"Journal of child psychology and psychiatry, and allied disciplines"},{"issue":"1\u20133","key":"10.1016\/j.schres.2020.03.006_bb0385","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.schres.2013.01.020","article-title":"Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia","volume":"146","author":"Zhang","year":"2013","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2020.03.006_bb0390","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1176\/appi.ajp.2018.17121363","article-title":"Schizophrenia polygenic risk score as a predictor of antipsychotic efficacy in first-episode psychosis","volume":"176","author":"Zhang","year":"2019","journal-title":"Am. J. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420301092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996420301092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:37:16Z","timestamp":1760297836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996420301092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":78,"alternative-id":["S0920996420301092"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2020.03.006","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Indicated association between polygenic risk score and treatment-resistance in a naturalistic sample of patients with schizophrenia spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2020.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}